PittsburghV1, Ncbi, Merge, bibRecord, 004210

Recent insights into the mode of action of memantine and ketamine

Identifieur interne : 004210 ( Ncbi/Merge ); précédent : 004209; suivant : 004211

Recent insights into the mode of action of memantine and ketamine

Auteurs : Jon W. Johnson ; Nathan G. Glasgow ; Nadezhda V. Povysheva

Source :

Current opinion in pharmacology [ 1471-4892 ] ; 2014.

RBID : PMC:4318755

Descripteurs français

KwdFr :
- Animaux, Antagonistes des acides aminés excitateurs (pharmacologie), Conception de médicament, Humains, Kétamine (pharmacologie), Mémantine (pharmacologie), Récepteurs du N-méthyl-D-aspartate (antagonistes et inhibiteurs), Thérapie moléculaire ciblée.
MESH :
- antagonistes et inhibiteurs : Récepteurs du N-méthyl-D-aspartate.
- pharmacologie : Antagonistes des acides aminés excitateurs, Kétamine, Mémantine.
- Animaux, Conception de médicament, Humains, Thérapie moléculaire ciblée.

English descriptors

KwdEn :
- Animals, Drug Design, Excitatory Amino Acid Antagonists (pharmacology), Humans, Ketamine (pharmacology), Memantine (pharmacology), Molecular Targeted Therapy, Receptors, N-Methyl-D-Aspartate (antagonists & inhibitors).
MESH :
- chemical , antagonists & inhibitors : Receptors, N-Methyl-D-Aspartate.
- chemical , pharmacology : Excitatory Amino Acid Antagonists, Ketamine, Memantine.
- Animals, Drug Design, Humans, Molecular Targeted Therapy.

Abstract

The clinical benefits of the glutamate receptor antagonists memantine and ketamine have helped sustain optimism that glutamate receptors represent viable targets for development of therapeutic drugs. Both memantine and ketamine antagonize N-methyl-d-aspartate receptors (NMDARs), a glutamate receptor subfamily, by blocking the receptor-associated ion channel. Although many of the basic characteristics of NMDAR inhibition by memantine and ketamine appear similar, their effects on humans and to a lesser extent on rodents are strongly divergent. Some recent research suggests that preferential inhibition by memantine and ketamine of distinct NMDAR subpopulations may contribute to the drugs' differential clinical effects. Here we review studies that shed light on possible explanations for differences between the effects of memantine and ketamine.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318755

DOI: 10.1016/j.coph.2014.11.006
PubMed: 25462293
PubMed Central: 4318755

Links toward previous steps (curation, corpus...)

to stream Pmc, to step Corpus: 000F95
to stream Pmc, to step Curation: 000F70
to stream Pmc, to step Checkpoint: 000800
to stream PubMed, to step Corpus: 000714
to stream PubMed, to step Curation: 000714
to stream PubMed, to step Checkpoint: 000714

Links to Exploration step

PMC:4318755

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Recent insights into the mode of action of memantine and ketamine</title>
<author><name sortKey="Johnson, Jon W" sort="Johnson, Jon W" uniqKey="Johnson J" first="Jon W." last="Johnson">Jon W. Johnson</name>
</author>
<author><name sortKey="Glasgow, Nathan G" sort="Glasgow, Nathan G" uniqKey="Glasgow N" first="Nathan G." last="Glasgow">Nathan G. Glasgow</name>
</author>
<author><name sortKey="Povysheva, Nadezhda V" sort="Povysheva, Nadezhda V" uniqKey="Povysheva N" first="Nadezhda V." last="Povysheva">Nadezhda V. Povysheva</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">25462293</idno>
<idno type="pmc">4318755</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318755</idno>
<idno type="RBID">PMC:4318755</idno>
<idno type="doi">10.1016/j.coph.2014.11.006</idno>
<date when="2014">2014</date>
<idno type="wicri:Area/Pmc/Corpus">000F95</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000F95</idno>
<idno type="wicri:Area/Pmc/Curation">000F70</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000F70</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000800</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000800</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">000714</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000714</idno>
<idno type="wicri:Area/PubMed/Curation">000714</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000714</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000714</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000714</idno>
<idno type="wicri:Area/Ncbi/Merge">004210</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Recent insights into the mode of action of memantine and ketamine</title>
<author><name sortKey="Johnson, Jon W" sort="Johnson, Jon W" uniqKey="Johnson J" first="Jon W." last="Johnson">Jon W. Johnson</name>
</author>
<author><name sortKey="Glasgow, Nathan G" sort="Glasgow, Nathan G" uniqKey="Glasgow N" first="Nathan G." last="Glasgow">Nathan G. Glasgow</name>
</author>
<author><name sortKey="Povysheva, Nadezhda V" sort="Povysheva, Nadezhda V" uniqKey="Povysheva N" first="Nadezhda V." last="Povysheva">Nadezhda V. Povysheva</name>
</author>
</analytic>
<series><title level="j">Current opinion in pharmacology</title>
<idno type="ISSN">1471-4892</idno>
<idno type="eISSN">1471-4973</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Drug Design</term>
<term>Excitatory Amino Acid Antagonists (pharmacology)</term>
<term>Humans</term>
<term>Ketamine (pharmacology)</term>
<term>Memantine (pharmacology)</term>
<term>Molecular Targeted Therapy</term>
<term>Receptors, N-Methyl-D-Aspartate (antagonists & inhibitors)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Antagonistes des acides aminés excitateurs (pharmacologie)</term>
<term>Conception de médicament</term>
<term>Humains</term>
<term>Kétamine (pharmacologie)</term>
<term>Mémantine (pharmacologie)</term>
<term>Récepteurs du N-méthyl-D-aspartate (antagonistes et inhibiteurs)</term>
<term>Thérapie moléculaire ciblée</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Receptors, N-Methyl-D-Aspartate</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Excitatory Amino Acid Antagonists</term>
<term>Ketamine</term>
<term>Memantine</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Récepteurs du N-méthyl-D-aspartate</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antagonistes des acides aminés excitateurs</term>
<term>Kétamine</term>
<term>Mémantine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Drug Design</term>
<term>Humans</term>
<term>Molecular Targeted Therapy</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Conception de médicament</term>
<term>Humains</term>
<term>Thérapie moléculaire ciblée</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P1">The clinical benefits of the glutamate receptor antagonists memantine and ketamine have helped sustain optimism that glutamate receptors represent viable targets for development of therapeutic drugs. Both memantine and ketamine antagonize <italic>N</italic>
-methyl-<sc>d</sc>
-aspartate receptors (NMDARs), a glutamate receptor subfamily, by blocking the receptor-associated ion channel. Although many of the basic characteristics of NMDAR inhibition by memantine and ketamine appear similar, their effects on humans and to a lesser extent on rodents are strongly divergent. Some recent research suggests that preferential inhibition by memantine and ketamine of distinct NMDAR subpopulations may contribute to the drugs' differential clinical effects. Here we review studies that shed light on possible explanations for differences between the effects of memantine and ketamine.</p>
</div>
</front>
</TEI>
<double pmid="25462293"><pmc><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Recent insights into the mode of action of memantine and ketamine</title>
<author><name sortKey="Johnson, Jon W" sort="Johnson, Jon W" uniqKey="Johnson J" first="Jon W." last="Johnson">Jon W. Johnson</name>
</author>
<author><name sortKey="Glasgow, Nathan G" sort="Glasgow, Nathan G" uniqKey="Glasgow N" first="Nathan G." last="Glasgow">Nathan G. Glasgow</name>
</author>
<author><name sortKey="Povysheva, Nadezhda V" sort="Povysheva, Nadezhda V" uniqKey="Povysheva N" first="Nadezhda V." last="Povysheva">Nadezhda V. Povysheva</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">25462293</idno>
<idno type="pmc">4318755</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318755</idno>
<idno type="RBID">PMC:4318755</idno>
<idno type="doi">10.1016/j.coph.2014.11.006</idno>
<date when="2014">2014</date>
<idno type="wicri:Area/Pmc/Corpus">000F95</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000F95</idno>
<idno type="wicri:Area/Pmc/Curation">000F70</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000F70</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000800</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000800</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Recent insights into the mode of action of memantine and ketamine</title>
<author><name sortKey="Johnson, Jon W" sort="Johnson, Jon W" uniqKey="Johnson J" first="Jon W." last="Johnson">Jon W. Johnson</name>
</author>
<author><name sortKey="Glasgow, Nathan G" sort="Glasgow, Nathan G" uniqKey="Glasgow N" first="Nathan G." last="Glasgow">Nathan G. Glasgow</name>
</author>
<author><name sortKey="Povysheva, Nadezhda V" sort="Povysheva, Nadezhda V" uniqKey="Povysheva N" first="Nadezhda V." last="Povysheva">Nadezhda V. Povysheva</name>
</author>
</analytic>
<series><title level="j">Current opinion in pharmacology</title>
<idno type="ISSN">1471-4892</idno>
<idno type="eISSN">1471-4973</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P1">The clinical benefits of the glutamate receptor antagonists memantine and ketamine have helped sustain optimism that glutamate receptors represent viable targets for development of therapeutic drugs. Both memantine and ketamine antagonize <italic>N</italic>
-methyl-<sc>d</sc>
-aspartate receptors (NMDARs), a glutamate receptor subfamily, by blocking the receptor-associated ion channel. Although many of the basic characteristics of NMDAR inhibition by memantine and ketamine appear similar, their effects on humans and to a lesser extent on rodents are strongly divergent. Some recent research suggests that preferential inhibition by memantine and ketamine of distinct NMDAR subpopulations may contribute to the drugs' differential clinical effects. Here we review studies that shed light on possible explanations for differences between the effects of memantine and ketamine.</p>
</div>
</front>
</TEI>
</pmc>
<pubmed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Recent insights into the mode of action of memantine and ketamine.</title>
<author><name sortKey="Johnson, Jon W" sort="Johnson, Jon W" uniqKey="Johnson J" first="Jon W" last="Johnson">Jon W. Johnson</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA. Electronic address: jjohnson@pitt.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
<author><name sortKey="Glasgow, Nathan G" sort="Glasgow, Nathan G" uniqKey="Glasgow N" first="Nathan G" last="Glasgow">Nathan G. Glasgow</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
<author><name sortKey="Povysheva, Nadezhda V" sort="Povysheva, Nadezhda V" uniqKey="Povysheva N" first="Nadezhda V" last="Povysheva">Nadezhda V. Povysheva</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25462293</idno>
<idno type="pmid">25462293</idno>
<idno type="doi">10.1016/j.coph.2014.11.006</idno>
<idno type="wicri:Area/PubMed/Corpus">000714</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000714</idno>
<idno type="wicri:Area/PubMed/Curation">000714</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000714</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000714</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000714</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Recent insights into the mode of action of memantine and ketamine.</title>
<author><name sortKey="Johnson, Jon W" sort="Johnson, Jon W" uniqKey="Johnson J" first="Jon W" last="Johnson">Jon W. Johnson</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA. Electronic address: jjohnson@pitt.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
<author><name sortKey="Glasgow, Nathan G" sort="Glasgow, Nathan G" uniqKey="Glasgow N" first="Nathan G" last="Glasgow">Nathan G. Glasgow</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
<author><name sortKey="Povysheva, Nadezhda V" sort="Povysheva, Nadezhda V" uniqKey="Povysheva N" first="Nadezhda V" last="Povysheva">Nadezhda V. Povysheva</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j">Current opinion in pharmacology</title>
<idno type="eISSN">1471-4973</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Drug Design</term>
<term>Excitatory Amino Acid Antagonists (pharmacology)</term>
<term>Humans</term>
<term>Ketamine (pharmacology)</term>
<term>Memantine (pharmacology)</term>
<term>Molecular Targeted Therapy</term>
<term>Receptors, N-Methyl-D-Aspartate (antagonists & inhibitors)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Antagonistes des acides aminés excitateurs (pharmacologie)</term>
<term>Conception de médicament</term>
<term>Humains</term>
<term>Kétamine (pharmacologie)</term>
<term>Mémantine (pharmacologie)</term>
<term>Récepteurs du N-méthyl-D-aspartate (antagonistes et inhibiteurs)</term>
<term>Thérapie moléculaire ciblée</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Receptors, N-Methyl-D-Aspartate</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Excitatory Amino Acid Antagonists</term>
<term>Ketamine</term>
<term>Memantine</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Récepteurs du N-méthyl-D-aspartate</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antagonistes des acides aminés excitateurs</term>
<term>Kétamine</term>
<term>Mémantine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Drug Design</term>
<term>Humans</term>
<term>Molecular Targeted Therapy</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Conception de médicament</term>
<term>Humains</term>
<term>Thérapie moléculaire ciblée</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The clinical benefits of the glutamate receptor antagonists memantine and ketamine have helped sustain optimism that glutamate receptors represent viable targets for development of therapeutic drugs. Both memantine and ketamine antagonize N-methyl-D-aspartate receptors (NMDARs), a glutamate receptor subfamily, by blocking the receptor-associated ion channel. Although many of the basic characteristics of NMDAR inhibition by memantine and ketamine appear similar, their effects on humans and to a lesser extent on rodents are strongly divergent. Some recent research suggests that preferential inhibition by memantine and ketamine of distinct NMDAR subpopulations may contribute to the drugs' differential clinical effects. Here we review studies that shed light on possible explanations for differences between the effects of memantine and ketamine.</div>
</front>
</TEI>
</pubmed>
</double>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004210 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 004210 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Amérique
   |area=    PittsburghV1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     PMC:4318755
   |texte=   Recent insights into the mode of action of memantine and ketamine
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:25462293" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a PittsburghV1

This area was generated with Dilib version V0.6.38.
Data generation: Fri Jun 18 17:37:45 2021. Site generation: Fri Jun 18 18:15:47 2021

	Serveur d'exploration sur Pittsburgh
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur Pittsburgh

Recent insights into the mode of action of memantine and ketamine

Recent insights into the mode of action of memantine and ketamine

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki